UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 6, 2020

InspireMD, Inc.

(Exact name of registrant as specified in its charter)

(888) 776-6804

(Registrant’s telephone number, including area code)

N/A

(Former Name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company [  ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

Item 8.01 Other Events.

On October 6, 2020, InspireMD, Inc. (the “Company”) issued a press release announcing the appointment of Patrick Jamnik as the Company’s Vice President of Business Development and Strategic Initiatives. In this new role, Mr. Jamnik will oversee the Company’s business development activities and play a key role in advancing its short and long-term strategic goals, with much of his focus being the U.S. market. Prior to joining the Company, Mr. Jamnik served in a commercial leadership role at Stryker Corp and, before that, as the director of global marketing at Stanmore Implants Worldwide.

In connection with Mr. Jamnik’s new position, the Company also announced on October 6, 2020 that it granted to Mr. Jamnik 162,920 shares of restricted stock and options to purchase 54,307 shares of the Company’s common stock, par value $0.0001 per share, as inducement awards outside the Company’s 2013 Long-Term Incentive Plan.

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.